# LiGeR-HN1 (petosemtamab): what clinicians are saying

> 321 statements from 37 sources (3 podcasts, 3 videos, 29 posts, 1 paper, 1 registry record), 182 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 8, 2026.

## Report

- Trial: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma
- NCT ID: NCT06525220
- Registry: https://clinicaltrials.gov/study/NCT06525220
- Sponsor: Genmab
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: petosemtamab plus pembrolizumab
- Indication: first-line PD-L1+ recurrent or metastatic HNSCC
- Version: v1.0.0, edition 1
- Accepted: 2026-11-08 UTC
- Last checked: 2026-11-08 UTC
- Release hash: bf5c3b240be60d0a85cbe7a605402ecd4b70bcfb1556960dac9cd47bf9b33325

## Counts

- Commentary sources screened: 76
- Sources cited by verified statements: 37
- Verified statements: 321
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 182
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 16
- Speakers cited: 16
- Cited speakers with a verified identity: 6
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 6
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 6
- By role and specialty (the abstract's specialty counts):
  - 3 physician
  - 2 physician, Medical oncology
  - 1 physician, Surgical oncology
- Organisational or shared accounts (not counted as people): 9

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A surgical oncologist reads LiGeR-HN1 favorably because of the reported size of its survival effect, but questions its position alongside pembrolizumab plus chemotherapy. In earlier treatment-selection context, the clinicians cited weigh symptoms and PD-L1 CPS; one medical oncologist considers monotherapy reasonable for low symptom burden when minimizing toxicity is a priority. Full results remain awaited to clarify absolute survival gains, HPV-specific effects and adverse-event rates.

## Question clinicians left open

What do clinicians still need to see to compare petosemtamab plus pembrolizumab with pembrolizumab plus chemotherapy in first-line PD-L1-positive recurrent or metastatic HNSCC, given LiGeR-HN1’s pembrolizumab-alone control?

From finding F1 (9 statements from 2 speakers in 9 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Commentators welcome the survival signal; one clinician asks how it compares with pembrolizumab plus chemotherapy
  - 9 statements from 2 speakers in 9 sources.
- F2. Clinicians condition trial consideration on resectability; one favors a chemotherapy-containing control for high symptom burden
  - 33 statements from 4 speakers in 5 sources, all podcasts or videos.
- F3. Clinicians welcome early EGFR activity; one makes future first-line use conditional on phase III confirmation
  - 19 statements from 3 speakers in 6 sources, 5 of them podcasts or videos.
- F4. Speakers and accounts seek HPV detail; one account predicts reliable efficacy only in HPV-negative disease
  - 27 statements from 7 speakers in 7 sources, 3 of them podcasts or videos.
- F5. Accounts credit the survival endpoint but say the absolute benefit cannot yet be sized
  - 31 statements from 2 speakers in 7 sources.
- F6. One clinician regards infusion reactions as manageable while stressing administration precautions and schedule differences
  - 16 statements from 2 speakers in 9 sources, 4 of them podcasts or videos.
- F8. One clinician conditionally favors upfront EGFR combinations; another asks whether response and PFS gains translate into lasting benefit
  - 15 statements from 4 speakers in 5 sources, 4 of them podcasts or videos.
- F9. Accounts offer differing, conditional readings of competing development routes
  - 37 statements from 4 speakers in 12 sources.

The full report also has 2 findings about other patients, lines of treatment or settings, after these trial findings under “Beyond the trial population”. They are not counted or listed on this page.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 9 | 9 | 9 | 2 | 2 |
| F2 | 33 | 20 | 5 | 4 | 4 |
| F3 | 19 | 12 | 6 | 3 | 4 |
| F4 | 27 | 15 | 7 | 7 | 5 |
| F5 | 31 | 8 | 7 | 2 | 4 |
| F6 | 16 | 14 | 9 | 2 | 5 |
| F8 | 15 | 10 | 5 | 4 | 4 |
| F9 | 37 | 16 | 12 | 4 | 5 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 6 | 1 | 0 | 2 | 0 | 11 | 1 | 9 posts and articles |
| F2 | 24 | 2 | 4 | 1 | 2 | 37 | 5 | 5 podcasts and video |
| F3 | 11 | 0 | 0 | 5 | 3 | 20 | 0 | 1 post or article, 5 podcasts and video |
| F4 | 11 | 10 | 0 | 3 | 3 | 28 | 5 | 4 posts and articles, 3 podcasts and video |
| F5 | 13 | 6 | 0 | 6 | 6 | 32 | 1 | 7 posts and articles |
| F6 | 6 | 1 | 0 | 6 | 3 | 19 | 1 | 4 posts and articles, 4 podcasts and video, 1 publication |
| F8 | 7 | 5 | 1 | 0 | 2 | 16 | 2 | 4 podcasts and video, 1 registry |
| F9 | 26 | 0 | 0 | 8 | 3 | 43 | 1 | 12 posts and articles |

### Trial dimensions

- Primary endpoint: Overall Survival (OS): F1 (2 shared claims), F5 (15 shared claims), F6 (1 shared claims), F9 (1 shared claims)
- Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR): F5 (14 shared claims)
- Secondary endpoints: F3 (1 shared claims), F5 (4 shared claims), F6 (1 shared claims), F8 (1 shared claims)
- Population and setting: F1 (1 shared claims), F2 (3 shared claims), F4 (19 shared claims), F8 (1 shared claims), F9 (1 shared claims)
- The comparison: F1 (5 shared claims), F2 (15 shared claims), F3 (1 shared claims), F5 (1 shared claims), F9 (2 shared claims)
- Safety and tolerability: F5 (3 shared claims), F6 (12 shared claims), F9 (1 shared claims)
- Design and conduct: F3 (1 shared claims), F5 (8 shared claims), F9 (2 shared claims)

## Abbreviations

- BICR: blinded independent central review
- CPS: combined positive score
- EGFR: epidermal growth factor receptor
- HCP: healthcare professional
- HNSCC: head and neck squamous cell carcinoma
- HPV: human papillomavirus
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- ORR: objective response rate
- OS: overall survival
- PD-L1: programmed death-ligand 1
- PFS: progression-free survival
- RECIST: Response Evaluation Criteria in Solid Tumors

## Examples from the report

Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.

- Physician, ex-US, identity checked against a staff page · podcast · Jul 2026 (finding F2): A physician sees a good opportunity to offer pembrolizumab plus a non-chemotherapy drug, particularly because the tumor is oral cavity and p16 negative, a disease profile they believe could potentially benefit from EGFR-targeted therapy.
- Physician, US, identity checked against NPI · podcast · May 2026 (finding F3): A physician considers emerging anti-EGFR strategies particularly exciting for HPV-negative disease, describing a foundation of studies combining cetuximab with pembrolizumab or nivolumab that showed better response rates and progression-free survival than historical pembrolizumab controls, particularly in HPV-negative patients.
- Medical oncologist, US, identity checked against NPI · podcast · Mar 2026 (finding F4): A medical oncologist awaits the phase III petosemtamab findings in HPV-positive disease.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 321 | Paid |
| Who said each statement, with each cited speaker's role and what confirmed it (NPI registry or staff page) | 16 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 37 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
| Verified speaker IDs as data (NPI, social and scholarly IDs) | 6 | 12-month plan add-on |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 6 of the 16 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, and it does not unlock who said what. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival (OS) | discussed | 17 | 8 |
| Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR) | discussed | 14 | 6 |
| Secondary endpoints | discussed | 7 | 7 |
| Population and setting | discussed | 29 | 8 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 31 | 13 |
| Safety and tolerability | discussed | 14 | 9 |
| Design and conduct | discussed | 11 | 6 |
| Biological rationale and earlier clinical evidence | discussed | 17 | 5 |
| Biomarker work-up and limits of treatment-selection shortcuts | discussed | 22 | 5 |
| Salvage feasibility and the local-versus-systemic decision | discussed | 19 | 3 |
| Upfront intensification, post-progression treatment and sequencing | discussed | 22 | 3 |
| Administration, supportive care and multidisciplinary readiness | discussed | 19 | 5 |
| Competitive evidence thresholds and conditional development consequences | discussed | 37 | 12 |
| Frontline treatment-selection context from HNSCC: Current and Emerging Therapeutic Strategies | discussed | 5 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 201 statements · 63%** (from 6 videos and episodes · about 34 per source) | | | |
| YouTube | 78 | 3 | 4 |
| Podcasts | 123 | 3 | 3 |
| **Posts · 112 statements · 35%** (from 29 posts · about 4 per source) | | | |
| X threads | 110 | 28 | 59 |
| LinkedIn posts | 2 | 1 | 2 |
| Bluesky threads | 0 | 0 | 8 |
| **Primary sources · 8 statements · 2%** (cited for context, not screened · from 2 sources · about 4 per source) | | | |
| Publications (primary source, cited for context) | 7 | 1 | not screened |
| Registry (primary source, cited for context) | 1 | 1 | not screened |

- Screened window: 2024-09-30 to 2026-11-06
- Cited window: 2024-12-02 to 2026-11-02
- Retrieved: 2026-11-08

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma
- Registry: NCT06525220 (https://clinicaltrials.gov/study/NCT06525220)
- Study IDs: MCLA-158-CL03 (GCT1158-03) · 2023-510323-30-00
- Sponsor: Genmab
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 699 (actual)
- Start: 2024-09-25 (actual)
- Primary completion: 2028-01 (estimated)
- Primary endpoint: Overall Survival (OS) (Up to approximately 3 years)
- Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR) (Up to approximately 2 years)
- Intervention: Petosemtamab (drug)
- Intervention: Pembrolizumab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on uncertain disease-control benefits of an alternative pembrolizumab combination in HPV-negative head and neck cancer; a view on dissent and anecdotal evidence when weighing immunotherapy doublets against single-agent treatment.
- 2 more clinician views in the sources used in this report are not yet captured as evidence in this edition.
- 1 passage in 1 source used in this report was not fully assessed for clinician views, so a view there may be missing from this edition.
- 169 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 15 sources about other trials or topics are not included; discussion that uses 3 names the trial shares with other things, without the trial's condition or setting, may be missing.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Social accounts, analyst relays and company-announcement summaries must not be counted as independently confirmed clinical consensus.
- Repeated podcast/video versions and near-identical posts can represent the same discussion or author rather than additional independent agreement.
- Discussion that does not name the trial or uses different transcription variants may be missing. One additional passage was not fully assessed, and a separate passage could not support a named attribution.
- Some passages cannot be assigned to a named speaker. They remain commentary from the relevant discussion and cannot establish agreement or disagreement between additional people.
- Clinical roles for several named social authors and accounts are unknown or unconfirmed. A source's description of someone as MD is attributed source wording, not independent confirmation.
- Phase III results discussed here are company-reported topline information relayed through commentary. Arm-level absolute outcomes, follow-up, event counts, detailed safety and quantitative subgroup results remain necessary for a fuller reading.
- Earlier phase II cohorts, later-line monotherapy findings, historical controls and personal numerical estimates cannot be substituted for LiGeR-HN1 outcomes or direct comparisons.
- No registry protocol file or exact product labels were available to check every design or approval description. The journal protocol describes planned methods rather than observed phase III results.
- Publication, post and repost dates do not establish a session date, a readout presentation date or a speaker's change of mind.
- Some connected discussion is incomplete: HPV-negative interpretations and an HPV-positive biological hypothesis for INBRX-106, the full alternative-agent durability comparison, an alternative combination's population-specific biological rationale, an episode's precise eligibility wording, and qualifications concerning immunotherapy after PD-1 failure are not fully represented. These summaries should not be treated as complete accounts of those exchanges.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-08 UTC: current edition
  - Routine maintenance: 1 fix (names, counts, text):
    - 2026-11-09 UTC: The trial's name is spelled as its investigators write it, “LiGeR-HN1” (NCT06525220), outside quotations (was “LEGER”, “LIGAR”, “LIGER”, “LIGHER”, “Liger”).

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-08 UTC. No changes.

## Offer

- Size: Deep · 321 verified statements · 182 from 6 confirmed clinicians
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $3,400
- 6 months of updates: $4,900
- 12 months of updates: $6,800
- Optional verified speaker identities (12-month updates only, product updates-12-identities; speakers are named and described in every report): the NPI and other verified IDs, to check that each statement is attributed to the right person, at $15 per identity-verified person in the edition at purchase (6 now), at most $1,950; people verified later in the term at no charge. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/liger-hn1-nct06525220
- Agents: POST https://www.erudio.com/api/orders with {"report": "liger-hn1-nct06525220", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=liger-hn1-nct06525220

## Cite

Erudio Health. LiGeR-HN1 (NCT06525220): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 8, 2026. https://www.erudio.com/reports/liger-hn1-nct06525220

## Machine access

- JSON: https://www.erudio.com/reports/liger-hn1-nct06525220.json
- Markdown: https://www.erudio.com/reports/liger-hn1-nct06525220.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/liger-hn1-nct06525220/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "liger-hn1-nct06525220"}`